Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study

Topical Anti-TNFα Agent Licaminlimab (OCS-02) Relieves Persistent Ocular Discomfort in Severe Dry Eye Disease: A Randomized Phase II Study

Lee Shettle,1 Eugene McLaurin,2 Joseph Martel,3 John W Seaman III,4 Georges Weissgerber5 1Shettle Eye Research, Inc, Largo, FL, USA; 2Total Eye Care, Memphis, TN, USA; 3Research Center, Martel Eye Medical Group, Rancho Cordova, CA, USA; 4Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA; 5No...

Full description

Bibliographic Details
Main Authors: Shettle L, McLaurin E, Martel J, Seaman JW III, Weissgerber G
Format: Article
Language:English
Published: Dove Medical Press 2022-07-01
Series:Clinical Ophthalmology
Subjects:
anti-tumor necrosis factor α
dry eye disease
single chain antibody fragment
topical treatment
Online Access:https://www.dovepress.com/topical-anti-tnf-agent-licaminlimab-ocs-02-relieves-persistent-ocular--peer-reviewed-fulltext-article-OPTH

Internet

https://www.dovepress.com/topical-anti-tnf-agent-licaminlimab-ocs-02-relieves-persistent-ocular--peer-reviewed-fulltext-article-OPTH

Similar Items